ESMO 2022

QoL and longterm toxicity

Reduction of peripheral neuropathy with taxane therapy

Dose-dense therapy is beneficial for all patients

My highlights of ESMO22

Long-term data on dose density therapy in chemotherapy

Dose-dense standard of care is the optimal care

Immuntherapy only for low risk patients?

Simple and cheap surgical technique may impact survival in early breast cancer

Endocrine response in eBC

Roadmap for the adjuvant setting

Dose dense is better

Consolidating data from prospective studies

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

DD is the champion!

Schéma dose-dense bénéfique pour toutes les patientes

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Datele trialurilor se consolideata

I miei punti salienti di ESMO22

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

Il vincitore e’ il dose dense!!

Status update - adjuvant IO. Are TILs prognostic?

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

Unmeet needs and my wishes for 2022!

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

How to deal with the negative SERD data?

Tailoring Adjuvant Therapy

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Sacituzumab govitecan for everybody!

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

Interim analysis shows promising data on Abema in the 1st Line

OS not significant, but re-assuring new data

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Survival benefit in endocrine sensitive patients

Another option for heavily pre-treated HR+ advanced breast cancer patients

HER2+ and still without chemotherapy

SG is a novel treatment option for HR+/HER2- disease

VEX has no place in chemotherapy of metastatic breast cancer

CDK4/6i could be an option for selected ER+/HER2+ disease

Update on biomarkers on ADCs of the DAISY trial

Exciting data, but Phase 3 studies are needed

New treatment option for heavily pre-treated patients with ER+ MBC

Survival benefit from SG in mBC

More therapy options for patients with HR+, HER2+ disease

Negative and yet positive?!

My highlights of ESMO22

ADC after ADC - is there any orientation?

TROPiCS-02 highlights

Discontinued development

The third in the bunch

Survie globale pas encore significative statistiquement mais données rassurantes

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

I miei punti salienti di ESMO22

Nouvelles données des analyses expolratoires dans l’étude DAISY

Sopravvivenza globale nello studio MONARCH3

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

Sacituzumab Govitecan: Un farmaco per tutte?

TROPiCS-02 highlights

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

ADAURA Update - preventing relapse or just delaying it?

Is OS really needed?

Neoadjuvant strategies for PD-L1 < 1 %

Window for treatment selection

INCREASE - to good to be true?

Pollution and lung cancer - one mechanism revealed

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Osimertinib - curing or delaying relapse?

Long term follow-up of ADAURA trial

Osimertinib stays standard adjuvant

Concurrent preoperative IO/CRT in early lung cancer

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

ADAURA revisited

ADAURA revisited

Langzeitdaten ADAURA

Eine Plattform für "take the winner"-Strategie

Osimertinib bleibt Standard adjuvant

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Pollution et cancer du poumon - un mécanisme mis en évidence

Osimertinib: una cura o ritarda la ripresa di malattia?

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Important data on borderline resectable patients

DFS matters!

Sotorasib vs. Docetaxel in mKRAS G12C

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Can IO be discontinued?

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

One more brick in the KRAS G12C wall

Is shorter immunotherapy equally effective and less physically demanding?

Preview on lung cancer highlights

5-year update on 1st line chemoimmunotherapy

Pneumonitis and T-DXd

Real-world data on Atezolizumab

Cemiplimab beyond progression?

A new step in treatment of KRAS G12C mutant NSCLC

New immunotherapy options for pts. ineligible to 1st line platinum therapy

Induction chemoimmunotherapy in borderline resectability?

DESTINY-Lung02 - better than the original?

5-year data on survival under immunotherapy

HER2 - the next actionable mutation in lung cancer?

Can we finally treat poor prognostic patients with immunotherapy?

Immunotherapy in unfit population? Perhaps...

Liquid biopsy monitoring in treatment decisions

Question about timing and duration of immunotherapy still unanswered

New therapy combination after progression on 1L osimertinib

5 years of chemoimmunotherapy: solid grounded

Poseidon and STK11/KEAP

If you don't look, vou don't find - once you found it, you'll treat it!

Atezolizumab better than vinorelbin in reduced performance status

Emerging IO mono options in the first line

Chemoimmunotherapy - improvement of survival after 5 years

The journey at KRAS G12C continues

Sotorasib: sweet and sour results

Sotorasib - a new standard of care?

Pneumonitis und T-DXd

Liquid Biopsy Monitoring zur Therapiesteuerung

Resultados Agridulces de Sotorasib

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

5 Jahre Chemo-Immuntherapie: starker Effekt

5-Jahresüberleben mit Immuntherapie

Un mattone in piu' nel muro del KRAS G12C

Chimio-immunothérapie - amélioration de la survie après 5 ans

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Immunoterapia nella popolazione non fit: forse

Poseidon und STK11/KEAP

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Die Reise bei KRAS G12C geht weiter

IO-IO neoadjuvant bei PD-L1 neg.

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Kann IO pausiert werden?

Données de vie réelle avec l’atezolizumab

Cemiplimab beyond progression?

Les études incontournables à l’ESMO 2022

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Sotorasib vs. Docetaxel bei mKRAS G12C

Neue Option der IO-Therapie in der Erstlinie

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Atezo besser als Vino bei PS2-3

Neue Therapiekombination in der Resistenz nach Osimertinib

Novel data and long-term efficacy of chemo-IO in mNSCLC

A positive study! With a question mark?

Heterogenity in the genetic landscape - little progress in molecular alterations

New strategies in immunotherapy

Exciting data for high-risk patients: is this the start of a new era?

More questions being raised

Adjuvant Immuntherapy in kidney cancer

New combo - triplet therapy for kidney cancer

Two negative studies question adjuvant approach in RCC

News in terms of adjuvant

Brief highlights about RCC & urothelial cancer from ESMO22

No value of IPI/Nivo in the adjuvant setting.

Place of triplet therapy

Immune-based peri-operative treatment in RCC: What went wrong?

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

Inmunoterapia adyuvante en el cancer renales

Terapia triple para cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Therapy combinations in RCC - what is the role of triplet therapy?

Shedding light on TKI/Checkpointinhibitor combinations

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Immunomodulation in combination with checkpointinhibiton

Brief highlights about RCC & urothelial cancer from ESMO22

EV + Pembro with excellent response rates

EV + pembrolizumab in cisplatin-ineligible patients

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Promising data, but beware of toxicity

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

ADCs - a possible therapeutic approach

Genetic testing before PARP therapy is useful

Optimizing cabazitaxel chemotherapy

QoL data from ARASENS triplet therapy study mHRPC

Combination of olaparib leads to promising results

Triplet therapy with darolutamide in prostate cancer

Length of hormone therapy after radiation

ADT + ENZA better choice than monotherapy

Radicals - ADT & Radiotherapy

Update on the PROpel study

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Biomarker data for better patients selection

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

PSA at 8-months as a biomarker

Further evaluation of PSA correlates

In older vulnerable - less is more

Cabazitaxel better tolerated in elderly men

IO + PARP without benefit in the allcomer situation

PSA efter 8 månader i PEACE-1 studien som biomarkör

Uppdatering i PROpel studien

Livskvalitetsuppföljning i ARASENS studien

Intimate partner violence in cancer patients

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

New group of substances for rare diseases

TILs - Fashion is the eternal return of the old

Addition of CPI to Radiochemotherapy in LA-HNSCC?

Novel approach von Biontech towards Cancer – game changing potential?!